Biological Mechanisms and Clinical Significance of BAP1 Mutations in Human Cancer
Open accessThe DOI matches its Crossref record; 178 of the 179 references it cites were found in a registry or an index.
Abstract
Among more than 200 BAP1-mutant families affected by the “BAP1 cancer syndrome,” nearly all individuals inheriting a BAP1 mutant allele developed one or more malignancies during their lifetime, mostly uveal and cutaneous melanoma, mesothelioma, and clear-cell renal cell carcinoma. These cancer types are also those that, when they occur sporadically, are more likely to carry somatic biallelic BAP1 mutations. Mechanistic studies revealed that the tumor suppressor function of BAP1 is linked to its dual activity in the nucleus, where it is implicated in a variety of processes including DNA repair and transcription, and in the cytoplasm, where it regulates cell death and mitochondrial metabolism. BAP1 activity in tumor suppression is cell type– and context-dependent. BAP1 has emerged as a critical tumor suppressor across multiple cancer types, predisposing to tumor development when mutated in the germline as well as somatically. Moreover, BAP1 has emerged as a key regulator of gene–environment interaction. This article is highlighted in the In This Issue feature, p. 1079
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“As reported by Bononi et al., BAP1 regulates ER-to-mitochondria calcium (Ca2+) release; thus, mutations in BAP1 lead to the intracellular Ca2+ reduction required for the regulation of OXPHOS enzymes, resulting in an impairment of mitochondrial respiration and a switch toward glycolysis [139,140].”
From Chronic Inflammation, Oxidative Stress and Metabolic Plasticity: Three Players Driving the Pro-Tumorigenic Microenvironment in Malignant Mesothelioma (2023) · cites this paper as [139]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“However, some malignancies in germline BAP1 mutation carriers, especially mesotheliomas, are much less aggressive, even if the exact mechanism is not completely understood [139].”
From Chronic Inflammation, Oxidative Stress and Metabolic Plasticity: Three Players Driving the Pro-Tumorigenic Microenvironment in Malignant Mesothelioma (2023) · cites this paper as [139]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Frequent Mutation of BAP1 in Metastasizing Uveal Melanomas
Harbour, J. W., Onken, M. D., Roberson, E. D. O., Duan, S., Cao, L., Worley, L. A., Council, M. L., Matatall, K. A., Helms, C., & Bowcock, A. M. (2010) · Science · doi:10.1126/science.1194472 · Cited by 1,462 · cited 4×
“Intriguingly, the opposite correlation with survival was observed in uveal melanoma (43, 100, 101, 106, 107), ccRCC (96, 108, 109), and cholangiocarcinoma (110), where somatic biallelic BAP1 mutations were associated with a metastatic phenotype and poor prognosis.”
BackgroundInfluentialGerlinger, M., Horswell, S., Larkin, J., Rowan, A. J., Salm, M. P., Varela, I., Fisher, R., McGranahan, N., Matthews, N., Santos, C. R., et al. (2014) · Nature Genetics · doi:10.1038/ng.2891 · Cited by 1,208 · cited 1×
“Following VHL inactivation, which is the signature and initiating event in ccRCC (85, 120, 121), a mutation of the second copy of BAP1 or PBRM1 likely leads to tumors of different grade and prognosis (19).”
BackgroundExome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma
Varela, I., Tarpey, P., Raine, K., Huang, D., Ong, C. K., Stephens, P., Davies, H., Jones, D., Lin, M.-L., Teague, J., et al. (2011) · Nature · doi:10.1038/nature09639 · Cited by 1,123 · cited 1×
“PBRM1, which encodes a switching defective/sucrose nonfermenting (SWI/ SNF) nucleosome remodeling complex protein (BAF180), is inactivated in approximately 50% of ccRCC (20, 116).”
BackgroundGermline BAP1 Mutations Predispose to Malignant Mesothelioma
Testa, J. R., Cheung, M., Pei, J., Below, J. E., Tan, Y., Sementino, E., Cox, N. J., Dogan, A. U., Pass, H. I., Trusa, S., et al. (2011) · Nature Genetics · doi:10.1038/ng.912 · Cited by 1,076 · cited 5×
“In 2011, Carbone’s team reported that germline BAP1 mutations predisposed to mesothelioma and uveal melanoma (14), the BAP1 cancer syndrome (6).”
BackgroundInfluentialSelf-citationBAP1 links metabolic regulation of ferroptosis to tumour suppression
Zhang, Y., Shi, J., Liu, X., Feng, L., Gong, Z., Koppula, P., Sirohi, K., Li, X., Wei, Y., Lee, H., et al. (2018) · Nature Cell Biology · doi:10.1038/s41556-018-0178-0 · Cited by 1,013 · cited 3×
“SLC7A11 imports extracellular cystine, which is subsequently converted to cysteine in cells; cysteine is a rate-limiting precursor for glutathione (GSH) biosynthesis; GSH is used as a cofactor by glutathione peroxidase 4 to reduce lipid reactive oxygen species (ROS) to lipid alcohols; overproduction of lipid ROS in ce…”
BackgroundBAP1 loss defines a new class of renal cell carcinoma
Peña-Llopis, S., Vega-Rubín-de-Celis, S., Liao, A., Leng, N., Pavía-Jiménez, A., Wang, S., Yamasaki, T., Zhrebker, L., Sivanand, S., Spence, P., et al. (2012) · Nature Genetics · doi:10.1038/ng.2323 · Cited by 959 · cited 23×
“In a study of 176 ccRCC at The University of Texas Southwestern (UTSW), where both IHC and DNA sequencing were performed, IHC results were interpretable in 175 tumors (20).”
BackgroundMethodInfluentialBueno, R., Stawiski, E. W., Goldstein, L. D., Durinck, S., De Rienzo, A., Modrusan, Z., Gnad, F., Nguyen, T. T., Jaiswal, B. S., Chirieac, L. R., et al. (2016) · Nature Genetics · doi:10.1038/ng.3520 · Cited by 919
Koppula, P., Zhang, Y., Zhuang, L., & Gan, B. (2018) · Cancer Communications · doi:10.1186/s40880-018-0288-x · Cited by 915 · cited 1×
“Among these genes, SLC7A11 (encoding the Solute Carrier Family 7 Member 11), an antiporter that imports cystine and exports glutamate (35), was repressed by BAP1.”
BackgroundGermline mutations in BAP1 predispose to melanocytic tumors
Wiesner, T., Obenauf, A. C., Murali, R., Fried, I., Griewank, K. G., Ulz, P., Windpassinger, C., Wackernagel, W., Loy, S., Wolf, I., et al. (2011) · Nature Genetics · doi:10.1038/ng.910 · Cited by 725 · cited 2×
“Once these independent studies were published (14, 16), the authors of these articles realized that multiple individuals in mesothelioma families L and W carried MBAITs and vice versa that multiple cases of mesothelioma had occurred in the families in which MBAITs had been discovered by dermatologists, thus confirming…”
BackgroundJensen, D. E., Proctor, M., Marquis, S. T., Gardner, H. P., Ha, S. I., Chodosh, L. A., Ishov, A. M., Tommerup, N., Vissing, H., Sekido, Y., et al. (1998) · Oncogene · doi:10.1038/sj.onc.1201861 · Cited by 723
Research works printed but not linked: 1
- Carbone, 2012, Nat Rev Cancer
Cited by
Targeting Ferroptosis as a Vulnerability in Cancer
Lei, G., Zhuang, L., & Gan, B. (2022) · Nature reviews. Cancer · doi:10.1038/s41568-022-00459-0 · Cited by 2,252
A pathology foundation model for cancer diagnosis and prognosis prediction
Wang, X., Zhao, J., Marostica, E., Yuan, W., Jin, J., Zhang, J., Li, R., Tang, H., Wang, K., Li, Y., et al. (2024) · Nature · doi:10.1038/s41586-024-07894-z · Cited by 580
Dong, L., Lu, D., Chen, R., Lin, Y., Zhu, H., Zhang, Z., Cai, S., Cui, P., Song, G., Rao, D., et al. (2022) · Cancer Cell · doi:10.1016/j.ccell.2021.12.006 · Cited by 390
Apoptotic cell death in disease—Current understanding of the NCCD 2023
Vitale, I., Pietrocola, F., Guilbaud, E., Aaronson, S. A., Abrams, J. M., Adam, D., Agostini, M., Agostinis, P., Alnemri, E. S., Altucci, L., et al. (2023) · Cell Death & Differentiation · doi:10.1038/s41418-023-01153-w · Cited by 361
Mitochondria-associated programmed cell death as a therapeutic target for age-related disease
Nguyen, T. T., Wei, S., Nguyen, T. H., Jo, Y., Zhang, Y., Park, W., Gariani, K., Oh, C.-M., Kim, H. H., Ha, K.-T., et al. (2023) · Experimental & Molecular Medicine · doi:10.1038/s12276-023-01046-5 · Cited by 325
Metadata
- Authors
- Carbone, M., Harbour, J. W., Brugarolas, J., Bononi, A., Pagano, I., Dey, A., Krausz, T., Pass, H. I., Yang, H., & Gaudino, G.
- Affiliations
- University of Hawaii Cancer Center (US)
- University of Miami (US)
- Harold C. Simmons Comprehensive Cancer Center (US)
- Genentech (US)
- University of Chicago (US)
- NYU Langone Health (US)
- Corresponding author
- Carbone, Michele
- ORCID
- Venue
- Cancer Discovery
- Published
- 2020-08-01
- Volume
- 10
- Issue
- 8
- Pages
- 1103-1120
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- PMC
- PMC8006752
- OpenAlex
- W3042684909
- Cited by
- 287
- References
- 179
- Citations by year
- 2026: 36 · 2025: 51 · 2024: 61 · 2023: 51 · 2022: 48 · 2021: 36 · 2020: 4
- FWCI
- 3.31
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Cancer Discovery (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- NIEHS (1R01ES030948-01)
- NCI (1R01CA237235-01A1, 1R01CA198138, U01CA111295-08)
- U.S. Department of Defense (CA150671)
- Department of Defense (W81XWH-15-1-0578)
- NIH (R01 CA125970, P30CA240139, P30EY014801, 1P50CA196516, R01CA175754, RP180192)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Health Sciences › Medicine › Ophthalmology › Ocular Oncology and Treatments
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Keywords
- BAP1, BAP1 mutation, tumor suppressor, uveal melanoma, cutaneous melanoma, mesothelioma, clear cell renal cell carcinoma, germline mutations, somatic mutations, DNA repair, transcription, cell death, mitochondrial metabolism, gene-environment interaction
- MeSH terms
- Humans, Kidney Neoplasms, Melanoma, Mutation, Skin Neoplasms, Uveal Neoplasms, Tumor Suppressor Proteins, Ubiquitin Thiolesterase
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Biological Mechanisms and Clinical Significance of BAP1 Mutations in Human Cancer. https://app.cochat.ai/papers/10.1158/2159-8290.cd-19-1220
- The paper
- Carbone, M., Harbour, J. W., Brugarolas, J., Bononi, A., Pagano, I., Dey, A., Krausz, T., Pass, H. I., Yang, H., & Gaudino, G. (2020). Biological Mechanisms and Clinical Significance of BAP1 Mutations in Human Cancer. Cancer Discovery. https://doi.org/10.1158/2159-8290.cd-19-1220
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.